2013
DOI: 10.3109/13880209.2013.840850
|View full text |Cite
|
Sign up to set email alerts
|

Alteration of the ERK5 pathway by hydroxysafflor yellow A blocks expression of MEF2C in activated hepatic stellate cellsin vitro: Potential treatment for hepatic fibrogenesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
3
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 38 publications
1
3
0
Order By: Relevance
“…It was reported that the aqueous extract of safflower reduced liver fibrosis and renal interstitial fibrosis by suppressing TGF-β1expression. 16) While, the effect of HSYA on the fibrosis of ARDS has not been reported up to now, our results indicate the protective effect of HSYA on early fibrosis of ARDS. Augmented expression of TGF-β1, α-SMA, Col I and Col III was decreased after the treatment of HSYA, especially at the 56 mg/kg dose.…”
Section: Discussionsupporting
confidence: 53%
“…It was reported that the aqueous extract of safflower reduced liver fibrosis and renal interstitial fibrosis by suppressing TGF-β1expression. 16) While, the effect of HSYA on the fibrosis of ARDS has not been reported up to now, our results indicate the protective effect of HSYA on early fibrosis of ARDS. Augmented expression of TGF-β1, α-SMA, Col I and Col III was decreased after the treatment of HSYA, especially at the 56 mg/kg dose.…”
Section: Discussionsupporting
confidence: 53%
“…In another study, SY improved cognitive function and astrocytes in an AD mouse model, the results showing that SY holds promise as a therapeutic approach for the treatment of AD [96]. The injection of 30 µm HSYA in rat hepatic stellate cells (HSCs) showed inhibition of HSC activation and cell proliferation, indicating it is a potential candidate for the prevention and treatment of hepatic fibrogenesis [97]. The effects of HSYA on lymphostatic encephalopathy (LE) induced brain changes in rats, supporting HSYA for the treatment of lymphostatic encephalopathy [98].…”
Section: Brain and Liver Disease Effectsmentioning
confidence: 99%
“…Some of the DE mRNAs were shown to participate in the process of liver cirrhosis. In addition to FOXP3 mentioned above, CXCL11 has been reported to be significantly associated with liver cirrhosis following viral hepatitis, and overexpression of MEF2C can activate HSCs[28, 29]. These immune-related mRNAs, which are linked with liver cirrhosis, are target genes of miR-219-5p.…”
Section: Discussionmentioning
confidence: 99%